| Type | Subsidiary |
| Parent Company | Boehringer Ingelheim |
| HQ | Genève, CH |
| Website | amaltherapeutics.com |
| Cybersecurity rating | AMore |
Amal Therapeutics is headquartered in Genève, CH
Viewing summary data as a guest
Sign up for free to see all data
Key People/Management at Amal Therapeutics
Laurence de Schoulepnikoff
COO
Madiha Derouazi
Founder and CEO
Greg Elson
VP, Manufacturing
Elodie Belnoue
Head of Research in Vivo
Jean-Francois Mayol
Head of Translational Research
Thomas Bogenrieder
Chief Clinical Officer
Amal Therapeutics Office Locations
Amal Therapeutics has an office in Genève
Genève, CH (HQ)
La Tulipe 64 Avenue de la Roseraie
Amal Therapeutics Financials and Metrics
Summary Metrics
Total Funding | $45.5 m |
Investors | BioMedPartners, Boehringer Ingelheim Venture Fund, Helsinn Investment Fund, Schroder Adveq, High-Tech Gründerfonds, VI Partners AG, Diego Braguglia, Riccardo Braglia, Frank Kalkbrenner, Andreas Wallnöfer |
In total, Amal Therapeutics had raised $45.5 m. Amal Therapeutics is a subsidiary of Boehringer Ingelheim
Amal Therapeutics Cybersecurity Score
Amal Therapeutics Online and Social Media Presence
Amal Therapeutics's Trends
Amal Therapeutics Blogs
September 08, 2021
AMAL Therapeutics to publish latest findings of its in vivo research team, in collaboration with Medical University of Innsbruck, on Nature Communication website
AMAL Therapeutics to publish latest findings of its in vivo research team, in collaboration with Medical University of Innsbruck, on Nature Communication website
Geneva, Switzerland, August 31, 2021 - AMAL Therapeutics announced today that the latest findings of its in vivo research …
July 01, 2021
AMAL Therapeutics to publish in vivo research outcomes in Frontiers in Immunology
AMAL Therapeutics to publish in vivo research outcomes in Frontiers in Immunology
Geneva, Switzerland, July 1, 2021 – AMAL Therapeutics announced today that the latest findings of its in vivo research team is on line on the Frontiers in Immunology website. Altogether, the results pre…
February 17, 2021
AMAL Therapeutics to publish R&D outcomes in Cancers
AMAL Therapeutics to publish R&D outcomes in Cancers
Geneva, Switzerland, February 17, 2021 – AMAL Therapeutics announced today that its recent research findings, in collaboration with Fox Chase Cancer Center, about a novel protein‐based vaccine against self‐antigen reducing the f…
January 20, 2020
CIMT Annual Meeting 2020
CIMT Annual Meeting 2020 May 5-7, 2020 / Mainz / Germany Jean-François Mayol attending
December 17, 2019
AACR Annual Meeting 2020
AACR Annual Meeting 2020 April 24-29, 2020 / San Diego / USA Madiha Derouazi presenting
November 04, 2019
ESMO Immuno-Oncology Congress 2019
ESMO Immuno-Oncology Congress 2019 December 11–14, 2019 / Geneva / Switzerland AMAL Team attending
Amal Therapeutics Frequently Asked Questions
Who are Amal Therapeutics key executives?
Amal Therapeutics's key executives are Laurence de Schoulepnikoff, Madiha Derouazi and Greg Elson.
How many employees does Amal Therapeutics have?
Amal Therapeutics has 22 employees.
Who are Amal Therapeutics competitors?
Competitors of Amal Therapeutics include Eutilex, Foghorn Therapeutics and Reflexion Medical.
Where is Amal Therapeutics headquarters?
Amal Therapeutics headquarters is located at La Tulipe 64 Avenue de la Roseraie, Genève.
Where are Amal Therapeutics offices?
Amal Therapeutics has an office in Genève.
How many offices does Amal Therapeutics have?
Amal Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies